MX2023007574A - "vacuna de arn contra variantes de sars-cov-2. - Google Patents
"vacuna de arn contra variantes de sars-cov-2.Info
- Publication number
- MX2023007574A MX2023007574A MX2023007574A MX2023007574A MX2023007574A MX 2023007574 A MX2023007574 A MX 2023007574A MX 2023007574 A MX2023007574 A MX 2023007574A MX 2023007574 A MX2023007574 A MX 2023007574A MX 2023007574 A MX2023007574 A MX 2023007574A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleic acid
- cov
- infection
- coronavirus
- variants
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- 241001678559 COVID-19 virus Species 0.000 abstract 1
- 241000711573 Coronaviridae Species 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nanotechnology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Plant Pathology (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
La presente invención se dirige a un ácido nucleico adecuado para usarse en tratamiento o profilaxis de una infección con un coronavirus, preferiblemente con a Coronavirus SARS-CoV-2, o un trastorno relacionado con tal infección, preferiblemente COVID-19. La presente invención también se dirige a composiciones, polipéptidos, y vacunas. Las composiciones y vacunas preferiblemente comprenden al menos una de dichas secuencias de ácidos nucleicos, preferiblemente secuencias de ácidos nucleicos en asociación a nanopartícula de lípido (LNP). La invención también se dirige a primeros y segundos usos médicos del ácido nucleico, la composición, el polipéptido, la combinación, la vacuna, y el kit, y a métodos de tratamiento o prevención de una infección por coronavirus, preferiblemente a infección por coronavirus.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063129395P | 2020-12-22 | 2020-12-22 | |
PCT/EP2021/052455 WO2021156267A1 (en) | 2020-02-04 | 2021-02-03 | Coronavirus vaccine |
EP2021069632 | 2021-07-14 | ||
EP2021069626 | 2021-07-14 | ||
PCT/IB2021/062127 WO2022137133A1 (en) | 2020-12-22 | 2021-12-21 | Rna vaccine against sars-cov-2 variants |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023007574A true MX2023007574A (es) | 2023-09-29 |
Family
ID=82120270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023007574A MX2023007574A (es) | 2020-12-22 | 2021-12-21 | "vacuna de arn contra variantes de sars-cov-2. |
Country Status (9)
Country | Link |
---|---|
US (3) | US11918643B2 (es) |
EP (1) | EP4267178A1 (es) |
JP (1) | JP2024502210A (es) |
KR (1) | KR20230164648A (es) |
AU (1) | AU2021405281A1 (es) |
BR (1) | BR112023012303A2 (es) |
CA (1) | CA3205569A1 (es) |
IL (1) | IL303976A (es) |
MX (1) | MX2023007574A (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
WO2021213924A1 (en) | 2020-04-22 | 2021-10-28 | BioNTech SE | Coronavirus vaccine |
US20230084012A1 (en) * | 2021-09-14 | 2023-03-16 | Globe Biotech Limited | Vaccine for use against coronavirus and variants thereof |
CN116200403A (zh) * | 2021-11-30 | 2023-06-02 | 石药集团巨石生物制药有限公司 | 预防突变株的新型冠状病毒mRNA疫苗 |
WO2023108083A2 (en) * | 2021-12-08 | 2023-06-15 | Yale University | Nanoparticle immunogenic compositions and vaccination methods |
US20230340033A1 (en) * | 2022-04-20 | 2023-10-26 | Inovio Pharmaceuticals, Inc. | Immunogenic Compositions Against SARS-COV-2 Variants And Their Methods Of Use |
WO2024026556A1 (en) * | 2022-05-02 | 2024-02-08 | Medicago Inc. | Modified coronavirus s protein |
WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
WO2024067861A1 (en) * | 2022-09-29 | 2024-04-04 | Suzhou Abogen Biosciences Co., Ltd. | MULTIVALENT NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM SARS-CoV-2 DELTA AND OMICRON STRAINS |
WO2024091258A1 (en) * | 2022-10-25 | 2024-05-02 | D4 Labs, Llc | Adjuvanted subcutaneously-administered polypeptide sars- cov-2 vaccines composition and methods |
US20240156949A1 (en) * | 2022-10-28 | 2024-05-16 | Glaxosmithkline Biologicals Sa | Nucleic Acid Based Vaccine |
US11911461B1 (en) | 2023-05-05 | 2024-02-27 | D4 Labs, Llc | Adjuvanted vaccines containing modified S1 Spike protein of SARS-CoV-2 variant C.1.2 for subcutaneous administration and methods of use |
Family Cites Families (245)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6134717A (en) | 1998-11-20 | 2000-10-24 | Morning Pride Manufacturing, L.L.C. | Protective garment with leg portions and with cuffs to prevent liquids from entering boots |
ES2356934T3 (es) | 2001-06-05 | 2011-04-14 | Curevac Gmbh | ARNm ESTABILIZADO CON UN CONTENIDO DE G/C AUMENTADO QUE CODIFICA PARA UN ANTÍGENO VIRAL. |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
JP4722481B2 (ja) | 2002-06-28 | 2011-07-13 | プロティバ バイオセラピューティクス リミテッド | リポソーム製造方法および装置 |
DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
US10188083B2 (en) | 2016-08-21 | 2019-01-29 | Daniel Michael Leo | Insect production systems and methods |
DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
ES2647491T3 (es) | 2004-05-21 | 2017-12-21 | Novartis Vaccines And Diagnostics, Inc. | Vectores del alfavirus para las vacunas del virus de la gripe |
US20060286124A1 (en) | 2004-06-30 | 2006-12-21 | Id Biomedical Corporation Of Quebec | Vaccine compositions and methods of treating coronavirus infection |
DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
EP2578685B1 (en) | 2005-08-23 | 2019-04-17 | The Trustees Of The University Of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
CA2659301A1 (en) | 2006-07-28 | 2008-02-07 | Applera Corporation | Dinucleotide mrna cap analogs |
DE102006035618A1 (de) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
WO2008157688A2 (en) | 2007-06-19 | 2008-12-24 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
BRPI0907087B1 (pt) | 2008-01-31 | 2021-08-17 | Curevac Ag | Molécula de rna, composição farmacêutica e seus usos no tratamento de doenças |
CN102066956B (zh) | 2008-04-14 | 2014-06-11 | 努沃尔特股份有限公司 | 电异常检测方法和系统 |
JP5475753B2 (ja) | 2008-04-15 | 2014-04-16 | プロチバ バイオセラピューティクス インコーポレイティッド | 核酸送達用の脂質製剤 |
PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
WO2011005799A2 (en) | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
RU2573409C2 (ru) | 2009-11-04 | 2016-01-20 | Дзе Юниверсити Оф Бритиш Коламбиа | Содержащие нуклеиновые кислоты липидные частицы и относящиеся к ним способы |
PT2506857T (pt) | 2009-12-01 | 2018-05-14 | Translate Bio Inc | Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas |
KR102505097B1 (ko) | 2009-12-07 | 2023-03-02 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 세포 리프로그래밍을 위한 정제된 변형 rna를 포함하는 rna 제제 |
WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
CA3009891C (en) | 2009-12-23 | 2020-09-15 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
CA3169291A1 (en) | 2010-07-06 | 2012-01-12 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of rna |
EP2590626B1 (en) | 2010-07-06 | 2015-10-28 | GlaxoSmithKline Biologicals SA | Liposomes with lipids having an advantageous pka-value for rna delivery |
US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
DK3243526T3 (da) | 2010-07-06 | 2020-02-17 | Glaxosmithkline Biologicals Sa | Levering af rna til at udløse flere immunsignalveje |
US8968746B2 (en) | 2010-07-30 | 2015-03-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
SI4008357T1 (sl) | 2010-08-31 | 2023-04-28 | Glaxosmithkline Biologicals Sa | Mali liposomi za dostavo imunogen-kodirajoče RNA |
HRP20221533T1 (hr) | 2010-08-31 | 2023-02-17 | Glaxosmithkline Biologicals Sa | Pegilirani liposomi za isporuku rna koja kodira imunogen |
CN103384515B (zh) | 2010-08-31 | 2017-02-15 | 诺华有限公司 | 适用于脂质体递送编码蛋白质的rna的脂质 |
DK3590949T3 (da) | 2010-10-01 | 2022-07-11 | Modernatx Inc | Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf |
WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
AU2012267578B2 (en) | 2011-06-08 | 2017-04-20 | Translate Bio, Inc. | Cleavable lipids |
JP2014520806A (ja) | 2011-07-06 | 2014-08-25 | ノバルティス アーゲー | Rna分子の送達のための有用なn:p比を有するリポソーム |
AU2012301715B2 (en) | 2011-08-31 | 2017-08-24 | Glaxosmithkline Biologicals S.A. | Pegylated liposomes for delivery of immunogen-encoding RNA |
EP2730549A4 (en) | 2011-09-08 | 2015-03-18 | Tokuyama Corp | SURFACTANT AGENT-COATED HEMIHYDRATE GYPSUM AND METHOD FOR MANUFACTURING THE SAME |
RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
US8969545B2 (en) | 2011-10-18 | 2015-03-03 | Life Technologies Corporation | Alkynyl-derivatized cap analogs, preparation and uses thereof |
US20130156849A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
SG10201607968WA (en) | 2012-03-27 | 2016-12-29 | Curevac Ag | Artificial nucleic acid molecules for improved protein or peptide expression |
KR20140139101A (ko) | 2012-03-27 | 2014-12-04 | 큐어백 게엠바하 | 5''top utr을 포함하는 인공 핵산 분자 |
JP6298039B2 (ja) | 2012-03-27 | 2018-03-20 | キュアバック アーゲー | 人工核酸分子 |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
WO2013151667A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides |
EP3498267A1 (en) | 2012-05-25 | 2019-06-19 | CureVac AG | Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings |
KR102134056B1 (ko) | 2013-02-22 | 2020-07-15 | 큐어백 아게 | Pd―1 경로의 억제 및 백신접종의 조합물 |
WO2014160243A1 (en) | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Purification and purity assessment of rna molecules synthesized with modified nucleosides |
RU2016109938A (ru) | 2013-08-21 | 2017-09-26 | Куревак Аг | Композиция и вакцина для лечения рака предстательной железы |
CN105451779A (zh) | 2013-08-21 | 2016-03-30 | 库瑞瓦格股份公司 | 增加rna编码蛋白表达的方法 |
CA2915730A1 (en) | 2013-08-21 | 2015-02-26 | Karl-Josef Kallen | A combination rsv/influenza a vaccine |
AU2014310932B2 (en) | 2013-08-21 | 2019-06-06 | CureVac SE | Composition and vaccine for treating lung cancer |
RU2712743C2 (ru) | 2013-08-21 | 2020-01-30 | Куревак Аг | Вакцина против бешенства |
BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
CA2925021A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Ag | Modified rna with decreased immunostimulatory properties |
AU2014375404C1 (en) | 2013-12-30 | 2020-11-19 | CureVac Manufacturing GmbH | Methods for RNA analysis |
JP6584414B2 (ja) | 2013-12-30 | 2019-10-02 | キュアバック アーゲー | 人工核酸分子 |
RU2717986C2 (ru) | 2013-12-30 | 2020-03-27 | Куревак Аг | Искусственные молекулы нуклеиновой кислоты |
WO2015135558A1 (en) | 2014-03-12 | 2015-09-17 | Curevac Gmbh | Combination of vaccination and ox40 agonists |
EP3129050A2 (en) | 2014-04-01 | 2017-02-15 | CureVac AG | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
SI3134131T1 (sl) | 2014-04-23 | 2022-04-29 | Modernatx, Inc. | Cepiva na osnovi nukleinskih kislin |
JP6571679B2 (ja) | 2014-04-25 | 2019-09-04 | トランスレイト バイオ, インコーポレイテッド | メッセンジャーrnaの精製方法 |
KR102459599B1 (ko) | 2014-06-10 | 2022-10-26 | 큐어백 리얼 이스테이트 게엠베하 | Rna생산을 증진하는 방법 및 수단 |
HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
US20180085391A1 (en) | 2014-08-08 | 2018-03-29 | Modernatx, Inc. | Compositions and methods for the treatment of ophthalmic diseases and conditions |
CA2963840A1 (en) | 2014-10-09 | 2016-04-14 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Long poly(a) plasmids and methods for introduction of long poly(a) sequences into the plasmid |
EP3230458B1 (en) | 2014-12-12 | 2020-02-19 | CureVac AG | Artificial nucleic acid molecules for improved protein expression |
US20170326225A1 (en) | 2014-12-16 | 2017-11-16 | Curevac Ag | Ebolavirus and marburgvirus vaccines |
US20160188710A1 (en) | 2014-12-29 | 2016-06-30 | Wipro Limited | METHOD AND SYSTEM FOR MIGRATING DATA TO NOT ONLY STRUCTURED QUERY LANGUAGE (NoSOL) DATABASE |
BR112017009835A2 (pt) | 2014-12-30 | 2017-12-26 | Curevac Ag | moléculas de ácido nucleico artificiais |
US10653768B2 (en) | 2015-04-13 | 2020-05-19 | Curevac Real Estate Gmbh | Method for producing RNA compositions |
CN107567497A (zh) | 2015-04-17 | 2018-01-09 | 库瑞瓦格股份公司 | Rna的冻干 |
ES2753259T3 (es) | 2015-04-22 | 2020-04-07 | Curevac Ag | Composición que contiene ARN para el tratamiento de enfermedades tumorales |
JP2018526321A (ja) | 2015-04-27 | 2018-09-13 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 適応免疫応答を誘導するためのヌクレオシド修飾rna |
EP3289077B1 (en) | 2015-04-30 | 2020-04-15 | CureVac AG | Method for in vitro transcription using an immobilized restriction enzyme |
ES2897823T3 (es) | 2015-04-30 | 2022-03-02 | Curevac Ag | Poli(N)polimerasa inmovilizada |
DK3294885T3 (da) | 2015-05-08 | 2020-08-10 | Curevac Real Estate Gmbh | Fremgangsmåde til at fremstille rna |
AU2016264027A1 (en) | 2015-05-15 | 2017-08-31 | Curevac Ag | Prime-boost regimens involving administration of at least one mRNA construct |
CN107530448A (zh) | 2015-05-20 | 2018-01-02 | 库瑞瓦格股份公司 | 包含长链rna的干粉组合物 |
SG11201708540VA (en) | 2015-05-20 | 2017-12-28 | Curevac Ag | Dry powder composition comprising long-chain rna |
EP4098743A1 (en) | 2015-05-29 | 2022-12-07 | CureVac AG | Method for adding cap structures to rna using immobilized enzymes |
US10760070B2 (en) | 2015-05-29 | 2020-09-01 | Curevac Real Estate Gmbh | Method for producing and purifying RNA, comprising at least one step of tangential flow filtration |
US20180296663A1 (en) | 2015-06-17 | 2018-10-18 | Curevac Ag | Vaccine composition |
IL283545B2 (en) | 2015-06-29 | 2023-09-01 | Acuitas Therapeutics Inc | Lipids and nanoparticulate lipid formulations for delivery of nucleic acids |
EP4239080A3 (en) | 2015-07-01 | 2023-11-01 | CureVac Manufacturing GmbH | Method for analysis of an rna molecule |
WO2017009376A1 (en) | 2015-07-13 | 2017-01-19 | Curevac Ag | Method of producing rna from circular dna and corresponding template dna |
EP3331555A1 (en) | 2015-08-05 | 2018-06-13 | CureVac AG | Epidermal mrna vaccine |
US20190024096A1 (en) | 2015-08-07 | 2019-01-24 | Curevac Ag | Process for the in vivo production of rna in a host cell |
PT4155409T (pt) | 2015-08-10 | 2024-02-26 | Curevac Mfg Gmbh | Método para aumentar a replicação de uma molécula de dna circular |
US20180237786A1 (en) | 2015-08-28 | 2018-08-23 | Curevac Ag | Artificial nucleic acid molecules |
EP3736261B1 (en) | 2015-09-17 | 2023-10-11 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
WO2017046801A1 (en) | 2015-09-17 | 2017-03-23 | Ramot At Tel-Aviv University Ltd. | Coronaviruses epitope-based vaccines |
CN116590285A (zh) | 2015-09-21 | 2023-08-15 | 垂林克生物技术有限公司 | 用于合成5’-加帽rna的组合物和方法 |
WO2017064146A1 (en) | 2015-10-12 | 2017-04-20 | Curevac Ag | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
DK3362461T3 (da) | 2015-10-16 | 2022-05-09 | Modernatx Inc | Mrna-cap-analoger med modificeret phosphatbinding |
WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
EP3362460A1 (en) | 2015-10-16 | 2018-08-22 | Modernatx, Inc. | Mrna cap analogs and methods of mrna capping |
WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
MD3718565T2 (ro) | 2015-10-22 | 2022-09-30 | Modernatx Inc | Vaccinuri împotriva virusului respirator |
PT3368507T (pt) | 2015-10-28 | 2023-02-07 | Acuitas Therapeutics Inc | Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos |
WO2018081480A1 (en) | 2016-10-26 | 2018-05-03 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
WO2017081082A2 (en) | 2015-11-09 | 2017-05-18 | Curevac Ag | Optimized nucleic acid molecules |
WO2017081110A1 (en) | 2015-11-09 | 2017-05-18 | Curevac Ag | Rotavirus vaccines |
US20180371392A1 (en) | 2015-12-21 | 2018-12-27 | Curevac Ag | Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay |
EP3701963A1 (en) | 2015-12-22 | 2020-09-02 | CureVac AG | Method for producing rna molecule compositions |
US11248223B2 (en) | 2015-12-23 | 2022-02-15 | Curevac Ag | Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
EP4289965A3 (en) | 2016-02-12 | 2024-02-21 | CureVac SE | Method for analyzing rna |
WO2017140345A1 (en) | 2016-02-15 | 2017-08-24 | Curevac Ag | Method for analyzing by-products of rna in vitro transcription |
US11723967B2 (en) | 2016-02-17 | 2023-08-15 | CureVac SE | Zika virus vaccine |
US11920174B2 (en) | 2016-03-03 | 2024-03-05 | CureVac SE | RNA analysis by total hydrolysis and quantification of released nucleosides |
EP3433361A1 (en) | 2016-03-24 | 2019-01-30 | CureVac AG | Immobilized inorganic pyrophosphatase (ppase) |
EP3445392A1 (en) | 2016-04-22 | 2019-02-27 | CureVac AG | Rna encoding a tumor antigen |
WO2017186928A1 (en) | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
EP3452493A1 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Nucleic acid molecules and uses thereof |
US20180126003A1 (en) | 2016-05-04 | 2018-05-10 | Curevac Ag | New targets for rna therapeutics |
US20210162037A1 (en) | 2016-05-04 | 2021-06-03 | Curevac Ag | Influenza mrna vaccines |
EP3464619A1 (en) | 2016-05-25 | 2019-04-10 | CureVac AG | Novel biomarkers |
AU2017277731B2 (en) | 2016-06-09 | 2021-02-18 | CureVac SE | Hybrid carriers for nucleic acid cargo |
EP3468612A1 (en) | 2016-06-09 | 2019-04-17 | CureVac AG | Hybrid carriers for nucleic acid cargo |
US20190336611A1 (en) | 2016-06-09 | 2019-11-07 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
WO2017212007A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Cationic carriers for nucleic acid delivery |
SG11201811432WA (en) | 2016-08-19 | 2019-03-28 | Curevac Ag | Rna for cancer therapy |
CA3036831A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
FR3056365A1 (fr) | 2016-09-19 | 2018-03-23 | Stmicroelectronics Sa | Procede de gestion du fonctionnement d'un circuit de bascule synchrone de retention de faible complexite, et circuit correspondant |
EP3529255A1 (en) | 2016-10-19 | 2019-08-28 | Arcturus Therapeutics, Inc. | Trinucleotide mrna cap analogs |
EP3532095A1 (en) | 2016-10-25 | 2019-09-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Prefusion coronavirus spike proteins and their use |
KR20190093816A (ko) | 2016-10-26 | 2019-08-26 | 큐어백 아게 | 지질 나노입자 mRNA 백신 |
US11279923B2 (en) | 2016-11-28 | 2022-03-22 | Curevac Ag | Method for purifying RNA |
WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
JP2020501545A (ja) | 2016-12-08 | 2020-01-23 | キュアバック アーゲー | 肝疾患の処置または予防のためのrna |
WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
WO2018115525A1 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Lassa virus vaccine |
EP3558355A2 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Henipavirus vaccine |
EP3595715A1 (en) | 2017-03-17 | 2020-01-22 | CureVac AG | Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy |
EP3595676A4 (en) | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | RNA VACCINES AGAINST ZOONOSES |
SG10202110491PA (en) | 2017-03-24 | 2021-11-29 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
WO2018211038A1 (en) | 2017-05-17 | 2018-11-22 | Curevac Ag | Method for determining at least one quality parameter of an rna sample |
US10724437B2 (en) | 2017-06-28 | 2020-07-28 | General Electric Company | Systems and methods for particle separator in a gas turbine engine |
US10988754B2 (en) | 2017-07-04 | 2021-04-27 | Cure Vac AG | Nucleic acid molecules |
US11602557B2 (en) | 2017-08-22 | 2023-03-14 | Cure Vac SE | Bunyavirales vaccine |
US20220233568A1 (en) | 2017-10-19 | 2022-07-28 | Curevac Ag | Novel artificial nucleic acid molecules |
RU2020117848A (ru) | 2017-11-08 | 2021-12-08 | Куревак Аг | Адаптиция последовательности phk |
CN111511928A (zh) | 2017-12-21 | 2020-08-07 | 库瑞瓦格股份公司 | 偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法 |
US20210361761A1 (en) | 2018-04-05 | 2021-11-25 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
EP4227319A1 (en) | 2018-04-17 | 2023-08-16 | CureVac SE | Novel rsv rna molecules and compositions for vaccination |
CN112384523A (zh) | 2018-05-16 | 2021-02-19 | 川斯勒佰尔公司 | 核糖阳离子脂质 |
CN112437767B (zh) | 2018-05-24 | 2023-10-27 | 川斯勒佰尔公司 | 硫酯阳离子脂质 |
WO2019232208A1 (en) | 2018-05-30 | 2019-12-05 | Translate Bio, Inc. | Cationic lipids comprising a steroidal moiety |
EP3801627A1 (en) | 2018-05-30 | 2021-04-14 | Translate Bio, Inc. | Phosphoester cationic lipids |
JP7441802B2 (ja) | 2018-05-30 | 2024-03-01 | トランスレイト バイオ, インコーポレイテッド | ビタミンカチオン性脂質 |
US20210260178A1 (en) | 2018-06-27 | 2021-08-26 | Curevac Ag | Novel lassa virus rna molecules and compositions for vaccination |
US20210261897A1 (en) | 2018-06-28 | 2021-08-26 | Curevac Ag | Bioreactor for rna in vitro transcription |
CA3118034A1 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Rna for malaria vaccines |
CA3122645A1 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Methods for rna analysis |
US10745919B1 (en) | 2019-07-26 | 2020-08-18 | Big Time Investment, Llc | Method and apparatus for installing a staircase assembly into a building |
CR20220108A (es) | 2019-08-14 | 2022-05-27 | Acuitas Therapeutics Inc | Nanopartículas lipídicas mejoradas para el suministro de ácidos nucleicos |
CN110647053A (zh) | 2019-09-19 | 2020-01-03 | 北京智行者科技有限公司 | 一种自动驾驶仿真方法及系统 |
JP2023507465A (ja) | 2019-12-20 | 2023-02-22 | キュアバック エスイー | 核酸を送達するための脂質ナノ粒子 |
WO2021142458A1 (en) | 2020-01-11 | 2021-07-15 | Sivec Biotechnologies Llc | A microbial system for production and delivery of eukaryote-translatable mrna to eukarya |
WO2021147025A1 (en) | 2020-01-22 | 2021-07-29 | The University Of Hong Kong-Shenzhen Hospital | Anti 2019-ncov vaccine |
US20220389050A1 (en) | 2020-01-24 | 2022-12-08 | Aim Immunotech Inc. | Therapeutic double stranded rna and methods for producing the same |
CR20220361A (es) | 2020-01-27 | 2022-12-12 | Valent Usa Llc | Una composición insecticida acuosa y sus métodos de uso |
US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
CA3168100A1 (en) | 2020-01-28 | 2021-08-05 | Codagenix Inc. | Deoptimized sars-cov-2 and methods and uses thereof |
EP4096710A1 (en) | 2020-01-28 | 2022-12-07 | ModernaTX, Inc. | Coronavirus rna vaccines |
US20210228707A1 (en) | 2020-01-28 | 2021-07-29 | Modernatx, Inc. | Coronavirus rna vaccines |
US11498944B2 (en) | 2020-01-31 | 2022-11-15 | Janssen Pharmaceuticals, Inc. | Compositions and methods for preventing and treating coronavirus infection—SARS-CoV-2 vaccines |
WO2021155760A1 (zh) | 2020-02-03 | 2021-08-12 | 康希诺生物股份公司 | 用于2019-nCoV型冠状病毒mRNA疫苗、制备方法及其应用 |
KR20220144416A (ko) | 2020-02-04 | 2022-10-26 | 큐어백 아게 | 코로나바이러스 백신 |
US11576966B2 (en) * | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
US11241493B2 (en) * | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
CN111821433B (zh) | 2020-02-06 | 2021-06-08 | 深圳市瑞吉生物科技有限公司 | mRNA疫苗及其合成方法、试剂盒 |
JP7438604B2 (ja) | 2020-02-07 | 2024-02-27 | モデルナティエックス インコーポレイテッド | SARS-COV-2 mRNAドメインワクチン |
EP4085131A4 (en) | 2020-02-10 | 2024-03-13 | Versitech Ltd | AGAINST THE SARS-CORONAVIRUS 2 IMMUNOGENE COMPOSITIONS, METHOD FOR THEIR PRODUCTION AND THEIR USE |
KR20220152226A (ko) | 2020-02-11 | 2022-11-15 | 사이토누스 테라퓨틱스, 인크. | 신속한 백신 플랫폼 |
KR20220140586A (ko) | 2020-02-11 | 2022-10-18 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | SARS-CoV-2 백신 |
EP4103584A1 (en) | 2020-02-12 | 2022-12-21 | La Jolla Institute for Immunology | Coronavirus t cell epitopes and uses thereof |
US20230127948A1 (en) | 2020-02-12 | 2023-04-27 | The Broad Institute, Inc. | Field deployable crispr-cas diagnostics and methods of use thereof |
CN113186203B (zh) | 2020-02-13 | 2022-12-30 | 斯微(上海)生物科技股份有限公司 | 治疗或者预防冠状病毒病的疫苗试剂 |
WO2021160346A1 (en) | 2020-02-13 | 2021-08-19 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
JP2023513913A (ja) | 2020-02-13 | 2023-04-04 | アンスティテュ・パストゥール | 麻疹ベクターを用いたcovid-19免疫原性組成物及びワクチン |
JP2023513611A (ja) | 2020-02-14 | 2023-03-31 | ゲオバックス インコーポレイテッド | Sars-cov2に対する免疫応答を誘導するためのワクチン及びその利用 |
WO2021163456A1 (en) | 2020-02-14 | 2021-08-19 | Epivax, Inc. | T cell epitopes and related compositions useful in the prevention, diagnosis, and treatment of covid-19 |
CN114096675A (zh) | 2020-02-14 | 2022-02-25 | 艾天穆股份有限公司 | 冠状病毒免疫原性组合物和其用途 |
EP4103230A1 (en) | 2020-02-14 | 2022-12-21 | University of Washington | Polypeptides, compositions, and their use to treat or limit development of an infection |
AU2021219304A1 (en) | 2020-02-14 | 2022-10-06 | Etherna Immunotherapies Nv | Intranasal mRNA vaccines |
GB202004007D0 (en) | 2020-03-19 | 2020-05-06 | Immodulon Therapeutics Ltd | Coronavirus |
CN111228475A (zh) | 2020-02-21 | 2020-06-05 | 赛诺(深圳)生物医药研究有限公司 | 用于预防新型冠状病毒的生物制品 |
WO2021000969A2 (zh) | 2020-02-23 | 2021-01-07 | 广州恩宝生物医药科技有限公司 | 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用 |
CN111333704B (zh) | 2020-02-24 | 2021-01-12 | 军事科学院军事医学研究院微生物流行病研究所 | 新型冠状病毒covid-19疫苗、制备方法及其应用 |
CN112300251B (zh) | 2020-02-24 | 2022-04-05 | 成都威斯克生物医药有限公司 | 抗SARS-CoV-2感染的蛋白及疫苗 |
CA3178344A1 (en) | 2020-03-31 | 2021-10-07 | The Trustees Of The University Of Pennsylvania | Universal influenza vaccine using nucleoside-modified mrna |
WO2021209970A1 (en) | 2020-04-16 | 2021-10-21 | Glaxosmithkline Biologicals Sa | Sars cov-2 spike protein construct |
CN111647053A (zh) | 2020-04-16 | 2020-09-11 | 军事科学院军事医学研究院生命组学研究所 | 多肽及其在新型冠状病毒检测、抗体或疫苗筛选中的应用 |
MX2022013264A (es) | 2020-04-22 | 2023-01-24 | Pfizer | Vacuna contra el coronavirus. |
WO2021213924A1 (en) | 2020-04-22 | 2021-10-28 | BioNTech SE | Coronavirus vaccine |
WO2021222304A1 (en) | 2020-04-27 | 2021-11-04 | Modernatx, Inc. | Sars-cov-2 rna vaccines |
CN111518175B (zh) | 2020-05-11 | 2021-02-26 | 广东珩达生物医药科技有限公司 | Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用 |
AU2021269783A1 (en) | 2020-05-11 | 2022-12-08 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
EP4153730A1 (en) | 2020-05-19 | 2023-03-29 | Gritstone bio, Inc. | Sars-cov-2 vaccines |
CN111606980B (zh) | 2020-05-27 | 2021-10-26 | 中国医学科学院基础医学研究所 | Sars-cov冠状病毒s2蛋白多肽及其应用 |
CN111606981B (zh) | 2020-05-27 | 2022-02-08 | 中国医学科学院基础医学研究所 | Sars-cov冠状病毒s1蛋白多肽及其应用 |
US11078242B1 (en) | 2020-05-28 | 2021-08-03 | Sotira Covid, Llc | Peptides for Covid-19 prevention and treatment |
BR112022023591A2 (pt) | 2020-05-29 | 2022-12-27 | Univ Texas | Proteína spike (s) do coronavírus modificada e métodos de uso da mesma |
US20230234992A1 (en) | 2020-06-05 | 2023-07-27 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
CN111732638B (zh) | 2020-07-02 | 2022-01-25 | 重庆博唯佰泰生物制药有限公司 | 一种针对SARS-CoV-2的疫苗 |
CN111778264B (zh) | 2020-07-14 | 2021-06-29 | 广州佰芮慷生物科技有限公司 | 基于新型腺病毒载体Sad23L和/或Ad49L的新型冠状病毒肺炎疫苗 |
CN112390863B (zh) | 2020-09-23 | 2022-11-01 | 厚朴生物科技(苏州)有限公司 | 改造的新冠病毒Spike蛋白胞外结构域及其应用 |
CN112266411B (zh) | 2020-09-25 | 2022-06-24 | 北京诺思兰德生物技术股份有限公司 | 一种新型冠状病毒疫苗及其应用 |
EP4217371A1 (en) | 2020-09-25 | 2023-08-02 | ModernaTX, Inc. | Multi-proline-substituted coronavirus spike protein vaccines |
CN112226445B (zh) | 2020-10-20 | 2021-05-11 | 成都欧林生物科技股份有限公司 | 编码SARS-CoV-2病毒刺突蛋白的核酸及其的应用 |
WO2022110099A1 (en) | 2020-11-30 | 2022-06-02 | Guangzhou Argorna Biopharmaceuticals Co., Ltd. | Coronavirus vaccines and uses thereof |
CA3208303A1 (en) | 2021-01-15 | 2022-07-21 | Modernatx, Inc. | Variant strain-based coronavirus vaccines |
CA3208486A1 (en) | 2021-01-15 | 2022-07-21 | Modernatx, Inc. | Variant strain-based coronavirus vaccines |
WO2022180219A1 (en) | 2021-02-25 | 2022-09-01 | Kosmatopoulos Kostantinos Kostas | Optimized vaccine to elicit a t cell immunity against sars-cov-2 |
WO2023051701A1 (zh) | 2021-09-29 | 2023-04-06 | 成都威斯津生物医药科技有限公司 | 抗SARS-CoV-2感染的mRNA、蛋白以及抗SARS-CoV-2感染的疫苗 |
WO2023064907A1 (en) | 2021-10-15 | 2023-04-20 | Yale University | Compositions and methods for vaccination against pathogenic coronavirus species and variants |
WO2023086961A1 (en) | 2021-11-12 | 2023-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sars-cov-2 spike fused to a hepatitis b surface antigen |
-
2021
- 2021-12-21 MX MX2023007574A patent/MX2023007574A/es unknown
- 2021-12-21 JP JP2023561934A patent/JP2024502210A/ja active Pending
- 2021-12-21 AU AU2021405281A patent/AU2021405281A1/en active Pending
- 2021-12-21 CA CA3205569A patent/CA3205569A1/en active Pending
- 2021-12-21 EP EP21836244.0A patent/EP4267178A1/en active Pending
- 2021-12-21 KR KR1020237024723A patent/KR20230164648A/ko unknown
- 2021-12-21 US US17/558,257 patent/US11918643B2/en active Active
- 2021-12-21 US US18/268,736 patent/US20240156946A1/en active Pending
- 2021-12-21 BR BR112023012303A patent/BR112023012303A2/pt unknown
-
2022
- 2022-05-31 US US17/829,004 patent/US11872280B2/en active Active
-
2023
- 2023-06-21 IL IL303976A patent/IL303976A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US11918643B2 (en) | 2024-03-05 |
US20220331422A1 (en) | 2022-10-20 |
JP2024502210A (ja) | 2024-01-17 |
CA3205569A1 (en) | 2022-06-30 |
US20240156946A1 (en) | 2024-05-16 |
BR112023012303A2 (pt) | 2024-02-15 |
EP4267178A1 (en) | 2023-11-01 |
IL303976A (en) | 2023-08-01 |
KR20230164648A (ko) | 2023-12-04 |
US11872280B2 (en) | 2024-01-16 |
US20220202930A1 (en) | 2022-06-30 |
AU2021405281A1 (en) | 2023-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022009460A (es) | Vacuna contra el coronavirus. | |
MX2023007574A (es) | "vacuna de arn contra variantes de sars-cov-2. | |
MX2022015132A (es) | Vacunas combinadas a base de acidos nucleicos. | |
MX2022016574A (es) | Inmunógenos de proteína de espicula (s) de coronavirus estabilizados y vacunas relacionadas. | |
WO2019193183A3 (en) | Novel yellow fever nucleic acid molecules for vaccination | |
BR112022014808A2 (pt) | Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2 | |
MX2020010941A (es) | Moleculas y composiciones novedosas de arn de vsr para vacunacion. | |
MX2018014573A (es) | Vacuna contra el virus del zika. | |
WO2022043551A8 (en) | Multivalent nucleic acid based coronavirus vaccines | |
WO2018115507A3 (en) | Henipavirus vaccine | |
WO2021191630A8 (en) | Coronavirus vaccine | |
PH12019500954A1 (en) | Vaccine against porcine parvovirus | |
PE20230171A1 (es) | Vacunas contra el coronavirus y metodos de uso | |
BR112022015626A2 (pt) | Composição e métodos de vacinas de mrna contra infecção de novo coronavírus | |
WO2022197720A3 (en) | Compositions and methods for treating coronavirus infection | |
BRPI1004898B8 (pt) | vetor expressão de superfície, microorganismo recombinate, vacina para tratar cervical e método para preparar um microorganismo | |
MX2021013111A (es) | Una vacuna de subunidad para el tratamiento o la prevencion de una infeccion del tracto respiratorio. | |
MX2022003758A (es) | Composiciones para el cuidado bucal que comprenden acido beta de lupulo y aminoacido. | |
UY39464A (es) | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 | |
BR112021019845A2 (pt) | Composições de vírus inativado e formulações de vacina contra zika | |
WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
MX2023012368A (es) | Vacuna de virus. | |
TW202140518A (zh) | 冠狀病毒疫苗 | |
BR112021023319A2 (pt) | Vetor viral | |
ATE420658T1 (de) | Imidazoquinolinamine als adjuvantien für hiv dna vakzine |